ity Center for Carbohydrate Science. He is an honorary member of the American Society for Clinical Investigation; a member of the editorial board of Glycobiology; and a member of the American Chemical Society, the American Society of Biological Chemists, and the Society for Complex Carbohydrates. Before joining Scripps, Dr. Paulson worked at Cytel Corporation (1990-1999) and the University of California at Los Angeles School of Medicine (1978-1990). He received his Ph.D. in biochemistry from the University of Illinois, Urbana-Champagne, in 1974. He holds numerous patents and has published over 230 scientific papers. His current research focuses on the roles of glycan-binding proteins that mediate cellular processes central to immune regulation and human diseases. He works at the interface of biology and chemistry to understand how the interaction of glycan-binding proteins with their ligands mediates cell-cell interactions, endocytosis, and cell signaling.

Ram Sasisekharan is Alfred H. Caspary Professor of Biological Engineering in the David H. Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology and a principal investigator in the Infectious Diseases Interdisciplinary Research Group of the SMART Centre in Singapore. In addition to developing analytical tools to study glycans, Dr. Sasisekharan’s group was the first to conduct detailed studies of a class of glycan-degrading enzymes that were revealed to be critical tools to uncover fundamental biological roles of glycans in diseases including cancer, cardiovascular biology, and infectious diseases. Dr. Sasisekharan has published over 150 manuscripts and filed 70 United States patents and patent applications. He was a founder of Momenta Pharmaceuticals and served as a Director through September 2010. The company was founded in 2001 based on Dr. Sasisekharan’s glycan sequencing platform, and the company has since leveraged this technology to produce the first biosimilar low molecular weight heparin. In 2005 he founded Cerulean Pharmaceuticals, which focuses on combination therapy using nanotechnology. In 2008 he founded Visterra Inc. with a focus on infectious diseases, and he currently serves on the board of this early-stage, venture-backed company. Dr. Sasisekharan is a consultant to and serves on the advisory boards of multiple biotechnology companies, venture funds, and nonprofit institutions involved in the translation of life-sciences innovation. He obtained his bachelor’s degree in physical sciences from Bangalore University and Ph.D. in medical sciences from Harvard Medical School.

Ajit P. Varki received basic training in physiology, medicine, biology, and biochemistry at Christian Medical College (Vellore, India), the University of Nebraska, and Washington University in St. Louis. He also has formal training and certification in internal medicine, hematology, and oncology.

The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement